Q4 2024 · 13F-HR
Cormorant Asset Management, LPholdings as filed
Filed 2025-02-14 · accession 0001583977-25-000001
$1.82B
Reported value
48
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $460.0M | 25.3% | 8,494,151 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $130.3M | 7.16% | 1,693,219 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $112.4M | 6.17% | 2,100,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $99.7M | 5.48% | 1,300,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $91.0M | 5.00% | 3,406,534 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $83.5M | 4.59% | 3,250,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $62.0M | 3.41% | 8,325,000 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $52.2M | 2.87% | 2,940,921 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $51.1M | 2.81% | 1,000,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $44.9M | 2.46% | 650,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $43.9M | 2.41% | 1,600,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $42.9M | 2.36% | 2,561,600 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $38.2M | 2.10% | 1,059,331 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $34.8M | 1.91% | 425,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $31.1M | 1.71% | 740,000 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $30.5M | 1.68% | 2,909,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $30.5M | 1.68% | 1,050,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $28.1M | 1.54% | 1,466,460 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $28.0M | 1.54% | 2,375,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $27.7M | 1.52% | 500,000 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $27.5M | 1.51% | 325,000 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $25.4M | 1.40% | 1,825,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $22.4M | 1.23% | 400,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $22.2M | 1.22% | 775,000 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $17.1M | 0.94% | 1,182,563 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $16.9M | 0.93% | 2,147,396 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $15.8M | 0.87% | 1,837,739 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $15.6M | 0.86% | 585,462 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $15.6M | 0.86% | 2,130,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $15.5M | 0.85% | 2,323,595 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $15.2M | 0.84% | 2,629,529 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $13.9M | 0.76% | 3,570,872 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $12.9M | 0.71% | 700,000 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $12.8M | 0.70% | 560,000 | Common | SOLE |
| 45256X103 | IBRX | IMMUNITYBIO INC | $7.7M | 0.42% | 3,000,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $5.6M | 0.31% | 250,000 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $5.3M | 0.29% | 500,000 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $4.7M | 0.26% | 1,394,336 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO INC | $4.2M | 0.23% | 603,027 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $4.2M | 0.23% | 593,043 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $3.3M | 0.18% | 425,000 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $3.2M | 0.18% | 300,000 | Common | SOLE |
| 682143102 | OMER | OMEROS CORP | $3.0M | 0.16% | 300,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $2.8M | 0.15% | 254,161 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $2.1M | 0.11% | 55,539 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $2.0M | 0.11% | 350,000 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $1.0M | 0.06% | 103,633 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $316,000 | 0.02% | 200,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.